I
Intensity Therapeutics Inc
NASDAQ:INTS
Intensity Therapeutics Inc
NASDAQ:INTS
Price:
4.1
USD
2.5%
Market Cap:
$11.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Intensity Therapeutics Inc
NASDAQ:INTS
|
US |
|
S
|
SIG PLC
DUS:QIG
|
UK |
|
N
|
NNIT A/S
CSE:NNIT
|
DK |
|
S
|
SIG PLC
SWB:QIG
|
UK |
|
SIG PLC
LSE:SHI
|
UK |
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| 9.3m | 4.5m | 1.3m | 8.6m | 2.6m | 11.9m | |
| 9.3m | 4.5m | 1.3m | 8.6m | 2.6m | 11.9m | |
| 0 | — | — | 6.2m | 0 | — | |
| 53.8k | 51.3k | 62.3k | — | — | — | |
| 258.1k | 139.7k | 76.2k | 688k | 773k | 788k | |
| 9.6m | 4.7m | 1.5m | 15.5m | 3.4m | 12.7m | |
| 490.2k | 318.1k | 139.1k | 147k | 122k | 96k | |
| 31.7k | 167.7k | 167.7k | 1.7m | 1.3m | 1.3m | |
| 10.1m | 5.2m | 1.8m | 17.3m | 4.8m | 14.1m | |
| 222.7k | 172.5k | 603.2k | 3m | 1.2m | 583k | |
| 1.1m | 1.5m | 1.9m | 911k | 536k | 1.6m | |
| 0 | 2m | 4.3m | 0 | 0 | 0 | |
| 1.3m | 3.7m | 6.8m | 4m | 1.8m | 2.1m | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 362.3k | 179.6k | 36k | 174k | 110k | 79k | |
| 1.7m | 3.9m | 6.9m | 4.1m | 1.9m | 2.2m | |
| 10m | 10m | 10m | 1k | 2k | 300 | |
| (23.2m) | (31.1m) | (38.7m) | (50.5m) | (66.8m) | (78.4m) | |
| 21.7m | 22.4m | 23.6m | 63.7m | 69.7m | 90.3m | |
| (50k) | 0 | — | — | — | (300) | |
| 8.4m | 1.3m | (5.1m) | 13.2m | 2.9m | 11.9m | |
| 10.1m | 5.2m | 1.8m | 17.3m | 4.8m | 14.1m | |
| 524k | 524k | 524k | 548.4k | 604.9k | 2.5m |
A cash-generative biotech transitioning from legacy MS to acquired growth platforms
A rapidly scaled RNAi platform moving from R&D losses to product profitability
A global oncology platform moving from costly R&D expansion toward scalable profitability
